2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities

Blueprint focus: ONCC Domain I.A.1 — At-risk populations, including disparities in culture, socioeconomic status, age, LGBTQIA status, gender identity, occupations, medical history, and geographic location. Expect stems that ask which patient is at greatest risk, which exposure explains a malignancy, or which barrier best explains a late-stage diagnosis.

---

Why Risk Stratification Comes First

Screening recommendations, genetic referral thresholds, and surveillance intervals all key off risk category. An advanced practice nurse who cannot place a patient into average, increased, or high risk cannot correctly apply any downstream guideline. Risk assessment is also where equity enters oncology practice: two patients with identical biology can have very different outcomes because one had a mammogram at 42 and the other first presented to an emergency department with a fungating mass.

Cancer risk factors divide into three broad tiers.

1. Non-modifiable host factors — age, biological sex, race and ancestry, height, and inherited germline variants.
2. Modifiable behavioral and metabolic factors — tobacco, alcohol, obesity, physical inactivity, diet, ultraviolet exposure, and hormone use.
3. Environmental, occupational, and infectious exposures — asbestos, radon, benzene, ionizing radiation, and oncogenic pathogens.

Age is the dominant single risk factor. Incidence rises steeply after age 50 for most epithelial cancers because carcinogenesis requires the accumulation of multiple somatic mutations. This is why almost every average-risk screening guideline begins in midlife, and why a malignancy diagnosed well below the guideline age should prompt a hereditary risk assessment.

---

Modifiable Behavioral and Metabolic Risk

---

Infectious Carcinogens

Roughly one in six cancers worldwide is attributable to an infectious agent, and several are directly preventable.

• Human papillomavirus (HPV) — causes virtually all cervical cancer and the majority of oropharyngeal, anal, vaginal, vulvar, and penile squamous carcinomas. HPV-positive oropharyngeal cancer is staged separately from tobacco-related disease because its prognosis is markedly better.
• Hepatitis B and C — hepatocellular carcinoma. Chronic carriers require surveillance ultrasound with or without alpha-fetoprotein every 6 months.
• Helicobacter pylori — gastric adenocarcinoma and gastric MALT lymphoma. Eradication alone can induce remission in localized MALT lymphoma.
• Epstein-Barr virus (EBV) — nasopharyngeal carcinoma, Burkitt lymphoma, post-transplant lymphoproliferative disorder, and a subset of Hodgkin lymphoma and gastric cancers.
• Human herpesvirus 8 (HHV-8) — Kaposi sarcoma and primary effusion lymphoma.
• HIV — an immunosuppressive amplifier of the AIDS-defining malignancies (Kaposi sarcoma, aggressive non-Hodgkin lymphoma, cervical cancer) and of anal and lung cancer risk.

---

Occupational, Environmental, and Iatrogenic Exposures

Take an occupational history when the histology or age of onset does not fit the patient's behavioral profile.

• Asbestos — mesothelioma (latency commonly 20 to 40 years) and lung cancer, multiplicatively increased by concurrent smoking. Shipyard, insulation, construction, and brake work.
• Radon — the second-leading cause of lung cancer in the United States; risk depends on home foundation and geography.
• Benzene — acute myeloid leukemia and myelodysplastic syndrome. Petrochemical work, rubber manufacturing, painting.
• Aromatic amines and polycyclic aromatic hydrocarbons — urothelial carcinoma. Dye, rubber, leather, and firefighting exposures.
• Ionizing radiation — leukemia, thyroid, and breast cancer; risk is highest with childhood or adolescent exposure and rises with cumulative dose.
• Prior cytotoxic therapy — alkylating agents and topoisomerase II inhibitors cause therapy-related myeloid neoplasms; this is covered in detail in the survivorship and second-primary sections.

---

Disparities: Culture, Socioeconomic Status, Identity, and Geography

The blueprint names these explicitly, so treat them as testable content rather than background.

Race and ancestry. Black Americans carry the highest overall cancer mortality rate of any US racial or ethnic group. Black men have roughly double the prostate cancer death rate of White men, and Black women die of breast cancer at a substantially higher rate than White women despite similar or lower incidence — a gap driven predominantly by later stage at diagnosis, longer time to treatment initiation, and higher rates of triple-negative disease. American Indian and Alaska Native populations have elevated kidney, liver, and stomach cancer mortality. Ancestry also carries biological signal: founder BRCA1/2 variants are enriched in people of Ashkenazi Jewish ancestry, and BRCA2-associated aggressive prostate cancer is more prevalent in men of African lineage.

Socioeconomic status and insurance. Uninsured and Medicaid-insured patients present at more advanced stage and have worse survival across nearly every tumor site. Cost-related medication non-adherence, transportation failure, inability to take unpaid leave, and low health literacy are all mediators the nurse practitioner can intervene on directly.

Sexual orientation and gender identity. Sexual and gender minority patients report lower rates of guideline-concordant screening, higher tobacco and alcohol use, and avoidance of care after prior discriminatory encounters. Two clinical rules follow. First, screen the organs the patient has, not the gender recorded in the chart: a transgender man who retains a cervix still needs cervical screening, and a transgender woman on long-term estrogen therapy needs an individualized breast screening discussion. Second, document an organ inventory at intake so that the screening plan does not depend on any clinician's assumption.

Geography. Rural residents face longer travel distances, fewer oncology subspecialists, lower clinical trial availability, and higher mortality from lung, colorectal, and cervical cancer. Appalachian and Deep South regions carry persistently elevated cervical and lung cancer mortality that tracks with screening access rather than with biology.

Medical history as a risk modifier. Inflammatory bowel disease raises colorectal risk in proportion to disease duration and extent; chronic immunosuppression after solid organ transplant multiplies skin cancer and post-transplant lymphoproliferative disorder risk; Barrett esophagus, atypical ductal hyperplasia, lobular carcinoma in situ, and monoclonal gammopathy of undetermined significance are all precursor states with their own surveillance obligations.

---

APRN Assessment Workflow

1. Take a three-generation family history and update it at least annually — new relative diagnoses change referral eligibility.
2. Quantify tobacco exposure in pack-years and record the quit date, because both figures gate lung cancer screening eligibility.
3. Record an organ inventory and prior surgical history rather than relying on recorded sex or gender.
4. Screen for social drivers: transportation, housing stability, food security, insurance status, caregiving obligations, and health literacy.
5. Convert findings into an explicit risk category, then apply the matching screening pathway and, if criteria are met, refer for genetic counseling.